Creative Medical Technology (CMT) Expands ADAPT Trial After FDA Clearance

Creative Medical Technology Holdings (CMT) announced on June 23, 2026, it received FDA clearance for an Investigational New Drug (IND) amendment, allowing the expansion of its ADAPT clinical trial. The trial, focused on treating Type 1 Diabetes with allogeneic stem cell therapy, will now enroll up to 20 patients. The expanded trial aims to further evaluate the therapy's safety and potential efficacy. The company's initial ADAPT trial (NCT04005219) previously demonstrated positive safety profiles and preliminary signs of efficacy. This expansion marks a significant step in developing a novel treatment for Type 1 Diabetes.